CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Vilazodone +1 moredrug
Likely dose
Vilazodone 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01999920
NCT01999920Phase 4Completed
CompareCT.gov

Vilazodone for Separation Anxiety Disorder

New York State Psychiatric Institute·interventional·Posted Dec 3, 2013·Updated Mar 7, 2018

In Brief

A Phase 4 clinical trial evaluating Vilazodone and Placebo for Separation Anxiety Disorder. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether Vilazodone (Viibryd), an SSRI and 5HT1a receptor agonist, is effective in treating Adult Separation Anxiety Disorder over a 12-week treatment course.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeparation Anxiety Disorder
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 3, 2013
Enrollment StartDec 1, 2013
Primary CompletionMar 1, 2017
Study CompletionDec 30, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.6 years ago

Interventions

Vilazodonedrug

10mg to 40mg per day for 12 weeks

Placebodrug

One to two pills per day for 12 weeks